CSG Holding Co., Ltd. (SHE:000012)

CTI BioPharma Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	3,489	3,422	3,077	4,605	2,766	2,127
Short-Term Investments	-	-	124.19	20	-	-
Trading Asset Securities	-	96	-	-	999.6	-
Cash & Short-Term Investments	3,489	3,518	3,201	4,625	3,766	2,127
Cash Growth	16.50%	9.89%	-30.78%	22.80%	77.08%	7.02%
Accounts Receivable	4,067	3,626	4,005	2,432	1,047	1,272
Other Receivables	166.38	114.86	117.84	116.99	115.96	164.24
Receivables	4,234	3,742	4,124	2,550	1,163	1,436
Inventory	1,887	1,588	1,590	1,784	1,094	815.16
Other Current Assets	644.68	647.77	527.07	367.78	284.05	261.72
Total Current Assets	10,254	9,495	9,442	9,327	6,307	4,640
Property, Plant & Equipment	18,555	18,582	17,492	13,774	11,034	11,039
Long-Term Investments	-	-	-	80	100	-
Goodwill	8.59	8.59	8.59	7.9	130.15	233.38
Other Intangible Assets	2,339	2,368	2,497	2,020	1,182	1,146
Long-Term Deferred Tax Assets	322.51	310	223.03	161.49	255.05	194.98
Long-Term Deferred Charges	71.46	-	-	46.76	72.02	49.15
Other Long-Term Assets	423.42	457.79	699.22	487.43	855.45	580.32
Total Assets	31,975	31,220	30,362	25,904	19,936	17,883
Accounts Payable	5,743	3,191	2,988	1,815	1,109	906.96
Accrued Expenses	215.97	689.62	848.49	933.15	808.83	750.46
Short-Term Debt	1,367	1,163	558.53	345.3	180.77	352.9
Current Portion of Long-Term Debt	2,211	2,081	1,207	2,443	466.1	927.53
Current Portion of Leases	-	87.78	42.02	38.9	0.86	-
Current Income Taxes Payable	97.85	24.13	50.02	38.33	81.33	90.3
Current Unearned Revenue	347.36	354.22	362.54	418.05	335.19	296.78
Other Current Liabilities	480.58	2,384	2,921	1,463	808.05	494.16
Total Current Liabilities	10,464	9,975	8,977	7,495	3,790	3,819
Long-Term Debt	6,243	6,152	6,222	4,354	3,466	2,847
Long-Term Leases	661.46	486.27	103.34	132.8	168.48	-
Long-Term Unearned Revenue	481.14	487.25	430.14	449.88	564.13	498.06
Long-Term Deferred Tax Liabilities	101.38	104.17	80.09	97.27	84.41	102.62
Other Long-Term Liabilities	15	0.92	1.25	-	-	-
Total Liabilities	17,966	17,218	15,825	12,528	8,073	7,267
Common Stock	3,071	3,071	3,071	3,071	3,071	3,071
Additional Paid-In Capital	590.74	649.17	649.17	655.42	597	597
Retained Earnings	9,726	9,710	10,211	9,016	7,593	6,373
Comprehensive Income & Other	162.42	106.38	120.37	113.16	166.5	172.09
Total Common Equity	13,549	13,536	14,051	12,855	11,427	10,213
Minority Interest	460.01	466.69	485.87	520.79	436.6	402.89
Shareholders' Equity	14,009	14,003	14,537	13,376	11,863	10,616
Total Liabilities & Equity	31,975	31,220	30,362	25,904	19,936	17,883
Total Debt	10,483	9,970	8,132	7,313	4,282	4,128
Net Cash (Debt)	-6,994	-6,452	-4,931	-2,689	-515.83	-2,001
Net Cash Per Share	-2.32	-2.18	-1.61	-0.87	-0.17	-0.65
Filing Date Shares Outstanding	3,071	3,071	3,071	3,071	3,071	3,071
Total Common Shares Outstanding	3,071	3,071	3,071	3,071	3,071	3,071
Working Capital	-209.45	-480.65	464.87	1,832	2,517	820.76
Book Value Per Share	4.41	4.41	4.58	4.19	3.72	3.33
Tangible Book Value	11,201	11,160	11,545	10,827	10,114	8,833
Tangible Book Value Per Share	3.65	3.63	3.76	3.53	3.29	2.88
Buildings	-	6,898	6,155	5,153	4,116	3,901
Machinery	-	14,849	15,298	13,536	11,344	11,449
Construction In Progress	-	5,350	4,325	2,520	2,458	1,893

Source: S&P Global Market Intelligence. Standard template. Financial Sources.